Abstract
Background: Patients with dementia have an increased risk of developing epilepsy, especially in patients with vascular dementia and Alzheimer’s disease. In selecting the optimal anti- epileptic drug (AED), the possible side effects such as drowsiness and worsening of cognitive function should be taken into consideration, together with co-morbidities and type of epilepsy.
Objective: The current systematic review investigates the efficacy, tolerability, and changes in cognitive function after administration of AED in patients with dementia and epilepsy.
Methods: We searched six databases, including MEDLINE and CENTRAL, checked reference lists, contacted experts, and searched Google Scholar to identify studies reporting randomized trials. Studies identified were independently screened, data extracted, and quality appraised by two researchers. A narrative synthesis was used to report findings.
Results: We included one study with 95 patients with Alzheimer’s disease randomized to either levetiracetam, lamotrigine, or phenobarbital. No significant differences were found for efficacy, but patients receiving levetiracetam showed an improvement in mini-mental state examination scores and had fewer adverse events.
Conclusion: High-quality evidence in the form of randomized controlled trials to guide clinicians in choosing an AED in patients with dementia and concomitant epilepsy remains scarce. However, levetiracetam has previously been shown to possibly improve cognition in patients with both mild cognitive impairment and Alzheimer’s disease, is better tolerated in the elderly population, and has no clinically relevant interaction with either cholinesterase inhibitors or NMDA receptor antagonists.
Keywords: Dementia, Alzheimer's disease, epilepsy, anti-epileptic medication, levetiracetam, older adults.
Current Alzheimer Research
Title:Pharmacological Medical Treatment of Epilepsy in Patients with Dementia: A Systematic Review
Volume: 18 Issue: 9
Author(s): Christian S. Musaeus*, Christer Nilsson, Chris Cooper, Milica G. Kramberger, Ana Verdelho, Elka Stefanova, Dorota Religa, Gunhild Waldemar and Kristian S. Frederiksen
Affiliation:
- Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet,Denmark
Keywords: Dementia, Alzheimer's disease, epilepsy, anti-epileptic medication, levetiracetam, older adults.
Abstract:
Background: Patients with dementia have an increased risk of developing epilepsy, especially in patients with vascular dementia and Alzheimer’s disease. In selecting the optimal anti- epileptic drug (AED), the possible side effects such as drowsiness and worsening of cognitive function should be taken into consideration, together with co-morbidities and type of epilepsy.
Objective: The current systematic review investigates the efficacy, tolerability, and changes in cognitive function after administration of AED in patients with dementia and epilepsy.
Methods: We searched six databases, including MEDLINE and CENTRAL, checked reference lists, contacted experts, and searched Google Scholar to identify studies reporting randomized trials. Studies identified were independently screened, data extracted, and quality appraised by two researchers. A narrative synthesis was used to report findings.
Results: We included one study with 95 patients with Alzheimer’s disease randomized to either levetiracetam, lamotrigine, or phenobarbital. No significant differences were found for efficacy, but patients receiving levetiracetam showed an improvement in mini-mental state examination scores and had fewer adverse events.
Conclusion: High-quality evidence in the form of randomized controlled trials to guide clinicians in choosing an AED in patients with dementia and concomitant epilepsy remains scarce. However, levetiracetam has previously been shown to possibly improve cognition in patients with both mild cognitive impairment and Alzheimer’s disease, is better tolerated in the elderly population, and has no clinically relevant interaction with either cholinesterase inhibitors or NMDA receptor antagonists.
Export Options
About this article
Cite this article as:
Musaeus S. Christian *, Nilsson Christer , Cooper Chris , Kramberger G. Milica , Verdelho Ana , Stefanova Elka , Religa Dorota, Waldemar Gunhild and Frederiksen S. Kristian , Pharmacological Medical Treatment of Epilepsy in Patients with Dementia: A Systematic Review, Current Alzheimer Research 2021; 18 (9) . https://dx.doi.org/10.2174/1567205018666211126121529
DOI https://dx.doi.org/10.2174/1567205018666211126121529 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Juvenile Neuronal Ceroid-Lipofuscinosis (Batten Disease): A Brief Review and Update
Current Molecular Medicine Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology New Chalcone Derivatives with Pyrazole and Sulfonamide Pharmacophores as Carbonic Anhydrase Inhibitors
Letters in Drug Design & Discovery AMPK As A Target in Rare Diseases
Current Drug Targets Editorial: [Hot Topic: Central Nervous System Drugs in the Treatment of Neurological Disorders]
Central Nervous System Agents in Medicinal Chemistry New Prospects for the Drug Treatment of Generalized Anxiety Disorder — A Systematic Review
Current Drug Therapy Advanced Intraoperative MR Imaging
Current Medical Imaging The Effects of Vitamin B in Depression
Current Medicinal Chemistry Cyclooxygenase and Neuroinflammation in Parkinsons Disease Neurodegeneration
Current Neuropharmacology Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Diagnosing and Treating Depression in Older and Oldest Old
Current Pharmaceutical Design Relationship Between Susceptibility to DMCM-Induced Generalized Motor Convulsions and Low-Affinity [3H]-Ouabain Binding in Membranes in Rat Brain
Current Molecular Pharmacology Classification of Normal and Epileptic EEG Signals Using Adaptive Neuro-Fuzzy Network Based on Time Series Prediction
Neuroscience and Biomedical Engineering (Discontinued) Synthesis and Evaluation of the Anticonvulsant Activity of 5-alkylthio-4- phenyl-2,4-dihydro-3H-1,2,4-triazol-3-one Derivatives
Letters in Drug Design & Discovery Editorial[Hot Topic:Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data
Current Drug Safety Decreased Expression of Sox-1 in Cerebellum of Rat with Generalized Seizures Induced by Kindling Model
CNS & Neurological Disorders - Drug Targets